This randomized, rater-blind, multicenter clinical trial will evaluate whether a personalized pharmaco-lifestyle intervention improves mental functioning in adults with severe mental illness, including schizophrenia, bipolar disorder, or major depressive disorder. Participants will be randomized to either a modular individualized intervention program or a structured psychoeducation control condition. The individualized intervention may include physical exercise, an anti-inflammatory diet, sleep intervention, social prescribing, semaglutide for eligible participants with overweight or obesity, and optional closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms. The primary outcome is change in the SF-36 Mental Component Summary score from baseline to Month 3.

开始日期2028-10-01

申办/合作机构

Ludwig-Maximilians-Universität München

NCT07430332

/ Not yet recruiting临床2期IIT

Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function

This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.

开始日期2027-09-01

申办/合作机构

Children's Hospital & Medical Center

NCT07731256

/ Not yet recruiting临床2期IIT

A Randomized-Controlled Trial of Semaglutide for Patients With Chronic Low Back Pain and Obesity

Low back pain is the leading cause of disability in the United States, and obesity is a major risk factor for its development. GLP-1 receptor agonists such as Semaglutide have emerged as effective weight loss agents that may also reduce chronic pain through weight reduction and other mechanisms. This randomized, double-blind, placebo-controlled trial will enroll 250 adults with chronic low back pain and obesity, randomized 1:1 to weekly Semaglutide 2.4 mg or placebo for 52 weeks. The primary outcome is change in low back pain severity, with secondary outcomes including pain-related disability and quality of life.

开始日期2027-02-01

申办/合作机构

Washington University School of Medicine

[+1]

100 项与司美格鲁肽 (诺和诺德) 相关的临床结果

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的转化医学

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的专利（医药）

登录后查看更多信息

381

项与司美格鲁肽 (诺和诺德) 相关的文献（医药）

2026-10-01·JOINT BONE SPINE

Role of the GAPDH-mediated glycolysis-senescence axis in osteoarthritis chondrocytes and its modulation by semaglutide

Article

作者: Zhu, Lin ; Wang, Leilei ; Liu, Dameng ; Wang, Yuanhang ; Pei, Lijia

OBJECTIVES:

This study aimed to identify key regulatory genes involved in chondrocyte senescence in osteoarthritis (OA) and to evaluate the therapeutic potential of the GLP-1 receptor agonist semaglutide.

METHODS:

Transcriptomic data of chondrocytes from OA and control groups were collected. Batch effects were corrected using Harmony, and differential expression analysis was performed with DESeq2 to identify significantly altered genes. Functional enrichment and pathway involvement were assessed using KEGG and Gene Set Enrichment Analysis (GSEA). Weighted gene co-expression network analysis (WGCNA) was applied to identify OA-related modules, and protein-protein interaction (PPI) networks were constructed to screen for hub genes. In vitro experiments included ROS detection, RT-PCR, and ELISA to evaluate oxidative stress, inflammatory mediators, and senescence-associated gene expression. Cell proliferation was assessed using CCK-8, and semaglutide treatment at different concentrations was applied to verify its regulatory effects.

RESULTS:

Transcriptomic analysis revealed significant upregulation of inflammatory and oxidative stress pathways in OA chondrocytes, accompanied by downregulation of cell cycle and DNA repair pathways, suggesting the accumulation of senescent cells. WGCNA and PPI network analyses identified GAPDH as a key hub gene, whose expression was markedly reduced in OA. In vitro validation confirmed decreased proliferative capacity, elevated ROS levels, and increased expression of p53, IL-6, and TGF-β in OA cells. Semaglutide treatment reversed GAPDH downregulation, improved proliferation, and reduced p53 and inflammatory cytokine levels, suggesting that it exerts protective effects through modulation of the glycolysis-senescence-inflammation axis.

CONCLUSION:

This study systematically elucidates the senescence-centered pathological characteristics of OA chondrocytes and identifies GAPDH as a pivotal regulator of glycolysis and senescence. Semaglutide alleviates OA progression by restoring GAPDH expression and modulating metabolic-senescence signaling. These findings provide a theoretical basis for metabolism- and senescence-targeted interventions in OA and offer new insights into potential molecular therapeutic targets.

2026-09-01·RESPIRATORY MEDICINE

GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis

Article

作者: Altschul, David J ; Sharma, Sunil ; Praveen, Niharika ; Essibayi, Muhammed Amir ; Latifi, Shahrzad ; Lakhani, Dhairya A ; Colasurdo, Marco ; Dmytriw, Adam A ; Azzam, Ahmed Y ; Bathla, Girish ; Rai, Pranjal ; Chen, Huanwen Alvin ; Malhotra, Ajay ; Yedavalli, Vivek S ; Salim, Hamza A ; Gandhi, Dheeraj

BACKGROUND:

Glucagon-like peptide-1 receptor agonists (GLP-1As) confer cerebrovascular benefits in diabetes and obesity, but their long-term effects in obstructive sleep apnea (OSA), which is frequently associated with obesity and linked to poor cerebrovascular outcomes, remain unclear.

METHODS:

We conducted a retrospective cohort study using the TriNetX US Collaborative Network between January 1st 2016 to December 31st 2025. Adults with OSA were identified; exposure was initiation of a GLP-1A within 6 months before up to 1 month after OSA diagnosis. Propensity score matching was performed 1:1. Outcomes were assessed at 1, 3, and 5 years and included ischemic stroke, intracranial hemorrhage, emergency department visits, inpatient hospitalizations, and all-cause mortality. Kaplan-Meier analyses and Cox proportional hazards models were used. CPAP-restricted and tirzepatide-specific subgroup analyses were also performed.

RESULTS:

After matching, 438,844 patients were included in each cohort. Across 1-, 3-, and 5-year follow-up, GLP-1A exposure was associated with lower hazards of ischemic stroke (HRs, 0.75, 0.83, and 0.87), intracranial hemorrhage (HRs, 0.44, 0.56, and 0.61), emergency department visits (HRs, 0.77, 0.86, and 0.87), inpatient hospitalizations (HRs, 0.59, 0.67, and 0.69), and all-cause mortality (HRs, 0.38, 0.49, and 0.54; all p < 0.001). Associations were directionally consistent in CPAP-restricted and tirzepatide-specific subgroup analyses.

CONCLUSIONS:

In this large real-world cohort of patients with OSA, GLP-1A exposure was associated with lower hazards of cerebrovascular events, healthcare utilization, and all-cause mortality across 1-, 3-, and 5-year follow-up. These findings are hypothesis-generating and require validation in prospective studies evaluating incretin-based therapies as potential adjuncts to standard OSA management.

2026-09-01·JOURNAL OF CLINICAL NEUROSCIENCE

GLP-1 receptor agonists and post-endovascular thrombectomy outcomes in acute ischemic stroke: a multicenter propensity score matched analysis

Article

作者: Lakhani, Dhairya A ; Salim, Hamza A ; Praveen, Niharika ; Latifi, Shahrzad ; Aggarwal, Eishvauk ; Essibayi, Muhammed Amir ; Altschul, David J ; Kakadiya, Jay ; Colasurdo, Marco ; Dmytriw, Adam A ; Azzam, Ahmed Y ; Gandhi, Dheeraj ; Dhaduk, Vidhi ; Bathla, Girish ; Rai, Pranjal ; Chen, Huanwen Alvin ; Yedavalli, Vivek S ; Malhotra, Ajay

BACKGROUND:

Glucagon-like peptide-1 receptor agonists (GLP-1As) have demonstrated cardiovascular and cerebrovascular benefits in high-risk populations, but their impact in patients with acute ischemic stroke (AIS) requiring endovascular thrombectomy (EVT) remains uncertain.

METHODS:

We performed a retrospective cohort analysis using the TriNetX Network, identifying adults (≥18 years) with AIS treated with EVT from January 1, 2016 through December 31, 2025. Patients with GLP-1A exposure within three months prior to EVT constituted the exposure cohort; those without served as comparators. This pre-index window was specified to eliminate immortal time bias, with follow-up beginning on the EVT date for both cohorts. Three-year outcomes included all-cause mortality and inpatient hospitalizations. One-to-one propensity score matching was applied using demographic, comorbidity, medication, and metabolic variables including individual National Institute of Health Stroke Scale scores, Hemoglobin A1c, and body mass index.

RESULTS:

Among 286 GLP-1A-exposed and 19,263 unexposed EVT-treated patients, 261 matched pairs were analyzed. GLP-1A use was associated with lower all-cause mortality (11.5% vs 29.9%; HR 0.334, 95% CI 0.219-0.508) and fewer inpatient hospitalizations (39.8% vs 54.8%; HR 0.514, 95% CI 0.398-0.663), both p < 0.001.

CONCLUSIONS:

Among EVT-treated AIS patients, GLP-1A exposure within three months prior to EVT was associated with improved survival and reduced inpatient hospitalizations.

15,181

项与司美格鲁肽 (诺和诺德) 相关的新闻（医药）

2026-07-28

·今日头条

中国减肥药王炸登场：一针管一月，三靶点，效果比礼来强51%

减肥药领域又有了新的进展，“每月注射一次”、“国产药比进口药好51%”等信息已经登上了热搜。其中五点需要保存起来，在将来会用到的地方。不要因为司美格鲁肽或者替尔泊肽每月注射一次的消息而停止使用目前使用的药物。歌礼制药向美国FDA提交的是新药临床试验申请，并不意味着该药品已经上市销售。从IND到最终获批一般需要3-5年的时间，在此期间还需要进行三期临床试验、成本评估以及生产审核等程序。目前你可以使用的、医生敢给你开的仍然是经过人体试验并且通过了数据审核之后才被允许使用的药物。贸然停止用药会失去已经证明有效的益处。 “比礼来最强组合强51%”这样的数据看上去很吓人，但是它是临床前的数据，在动物模型上测得的结果。所谓的临床前就是指在动物身上做实验得到的数据，原文中也提到是用DIO大鼠模型做的实验。虽然可以作为人类疗效的一个参考指标，但是人和鼠的代谢系统、药物代谢率以及副作用的表现都存在很大的不同。多年的行业数据显示出，在动物实验中表现出色的药物到了人体内之后往往效果大打折扣或者完全失效。真正决定该药是否具有竞争力的时候要等到I期、II期的人体临床试验数据出来之后才能确定。歌礼公司的I期结果预计到2027年才会公布，在此之前，“比礼来最强组合强51%”只是一条需要关注的方向性信号而已。依从性的提高是真实的，“每月一针”的技术原理要比“少打几次”更加值得我们去关注。歌礼所采用的是SALD自组装脂质储存库技术，即把药物注入人体内之后并不会马上扩散开来，在皮下会形成一个小的缓释库，药物从中缓慢释放出来。这就使得血药浓度曲线更加平缓，并不是每周一次注射就会出现注射之后几天内浓度骤升然后又迅速下降的情况。稳定的血药浓度可以带来两个方面的益处：第一就是体重控制的效果不会忽高忽低；第二就是在用药后的几天内出现恶心、呕吐等副作用的可能性也会降低很多。如果患者正在使用GLP-1类药物并且因为副作用而生活质量受到影响的话，那么该技术带来的好处就显得尤为重要了。但是目前还不能用它来治疗病人。 Amylin受体又成了新一轮药物研发的重点研究对象，但是很少有人知道。GLP-1类药物的主要功能是抑制食欲、延缓胃排空，但是很多患者在服用六个月之后效果就会减弱或者产生耐药性。Amylin受体的作用机理和GLP-1不同：它主要负责调节餐后的饱腹感、减慢胃排空速度以及降低进食欲望，在一定程度上可以弥补GLP-1药物所存在的缺陷。ASC36和ASC36_35复方就是把Amylin靶点和GLP-1/ GIP双重靶点结合起来形成的三种不同的作用途径。例如：如果使用了GLP-1药物之后出现了减重停滞或者胃肠道副作用难以忍受的情况，在将来可能会有一条新的选择。但是目前Amylin类药物长期的安全性和体重反弹率的数据还不完善，所以应该先考虑现有药物是否仍然有效，而不应过早地押宝于新的靶点上。目前在中国进行Amylin研发并且已经到了提交IND阶段的企业只有歌礼医药一家。信达生物、恒瑞医药的主要研究方向是GLP-1系列药物，并没有关于Amylin药物的信息。歌礼的核心产品线包括口服小分子药、每月注射一次的药物以及多个靶点的复方药，大部分都处于临床前或者IND早期阶段。如果你关心的是品牌的话，真正竞争对手就是诺和诺德的司美格鲁肽（已经上市）和礼来公司的替尔泊肽（也已经上市）。国产Amylin药物最早也要等到2029年至2030年才能面世，在那个时候如果你仍然存在减肥或者血糖控制困难的问题，手中就会多出一种选择，但是现在还完全没有必要考虑这个问题，先把现有的药物用好用对。了解了上面的内容之后，要关注的地方就不是数据效应了，而是人体数据第一次公开的时候有没有副作用小、减肥效果好的方案出现，并且在以后会不会有类似的方案出现。把上面的内容记下来，在需要的时候不用再去查找。具体的治疗还是要听医生的话。

2026-07-28

·汇聚南药

甘李药业：锚与帆

在中国生物医药的版图上，甘李药业是一个绕不过去的名字。 1998年成立至今，近二十八年，它从“中国第一家掌握产业化生产重组胰岛素类似物技术”的拓荒者，走到了今天横跨代谢、肿瘤、自身免疫、降血脂等多领域的创新药企。提起甘李，第一印象仍是胰岛素龙头，这是它最坚固的锚，也是所有技术延伸的起点。但随着GLP-1减重赛道的爆发、PROTAC等前沿技术的落地，甘李正在讲一个新故事。锚还扎在原地，帆已隐约升起来了。 01 胰岛素：锚甘李的起家史，几乎就是中国三代胰岛素国产化的缩影。从长效甘精胰岛素注射液出发，逐步覆盖了速效、预混三大细分市场，核心产品矩阵包括甘精胰岛素、赖脯胰岛素、门冬胰岛素及其预混制剂，加上人胰岛素品种，实现了三代胰岛素的全品类覆盖。这一布局不仅在国内站稳了脚跟，更在海外多个市场完成了基础、速效、预混制剂的全系列注册获批。 2024年胰岛素专项接续集采中，甘李类似物集采协议量在中选企业中排名第一。2025年，甘李胰岛素全品类采购规模仅次于诺和诺德，三代胰岛素协议量在行业内占比达30%。甘李没有止步于药，还向下延伸到了注射器械。可重复使用的胰岛素注射笔和一次性注射笔用针头构成了“药品加器械”的闭环。针头早在2020年便获得美国FDA批准。这套协同模式在集采常态化背景下，成了维持毛利结构与市场渗透率的隐形筹码。 2025年，胰岛素国内收入35.06亿元，同比增长39.23%。这笔现金流是甘李的锚，也是它所有技术外延的底舱。多肽合成、长效化修饰、蛋白纯化，这些在胰岛素上磨出来的工艺积累，构成了后续GLP-1、抗体、核酸药物铺开的底层支撑。图：甘李药业的“锚” 但集采的压力并未消失。胰岛素专项接续采购中，甘李虽然拿下了最高的协议量，却是在大幅降价的前提下实现的。接续采购价格相比首次集采进一步下探，部分品种降幅超过20%。这意味着在协议量增长的同时，单支胰岛素的实际利润空间在持续收窄。 2025年国内胰岛素收入同比增长39.23%，很大程度上是“以价换量”的结果，后续再靠量的扩张来对冲价的压力，空间只会越来越小。此外，海外胰岛素市场的低价竞争也在加剧。印度Biocon等仿制药企在东南亚和非洲市场持续扩张，甘李的出海并不轻松。 02 代谢外延：帆糖尿病、肥胖、血脂异常同属代谢综合征的核心组分。甘李从降糖向减重和降脂延伸，逻辑上没有断层。在GLP-1受体激动剂的热潮中，甘李押注了差异化明显的双周制剂博凡格鲁肽。与主流周制剂相比，它将注射频次拉长至每两周一次，年注射次数可减少约一半。52周减重幅度达18.54%，中国减重关键III期和美国关键II期均已达到主要终点，同时拓展至肥胖合并阻塞性睡眠呼吸暂停等细分适应症。在胰岛素升级维度，第四代基础胰岛素周制剂GZR4已进入全球III期临床，两项关键III期研究已到达主要终点。基础胰岛素和GLP-1受体激动剂的固定比例复方周制剂、双胰岛素复方周制剂等组合疗法也在同步推进，试图在控糖、护心肾、减重的综合管理上给出更完整的方案。降血脂方向同样有迹可循。从已申请专利情况来看，针对PCSK9、APOC3等靶点的长效核酸或小分子抑制剂已有潜在储备。结合GLP-1与胰岛素复方在改善血脂参数上的协同效应，这条线正逐步切入心血管-肾脏-代谢综合征的更大版图。图：甘李的“帆” 但必须清醒地看到，博凡格鲁肽面对的是礼来和诺和诺德已经筑起的厚重壁垒。替尔泊肽和司美格鲁肽的年销售额都在百亿美元量级，品牌认知和医生处方习惯已经根深蒂固。双周制剂的依从性优势能否转化为市场份额，取决于商业化执行力和医保准入节奏，而礼来和诺和诺德不会坐等对手追赶。 GZR4的全球III期数据尚未完全读出，周制剂胰岛素的安全性需要更大样本和更长随访来验证。降脂管线目前仍处于专利储备阶段，离临床验证还有相当距离。在代谢领域的扩张逻辑是清晰的，但在巨头林立的赛道上，能抢到多大的蛋糕还需要持续跟踪。 03 技术平台：五条线甘李能从单一蛋白药企走向多技术平台，背后是五条研发线的数箭并发。 1.多肽技术平台是它的老本行。 NovaPeptide支撑胰岛素产业化，SupOraTide探索口服多肽，Longlastide瞄准月制剂乃至季度制剂。氨基酸定点突变、脂肪酸链偶联增强白蛋白结合力等技术，直接催生了博凡格鲁肽等长效产品。平台累计申请专利超60项，含11项PCT专利。 2.PROTAC技术平台是向肿瘤和自身免疫领域突进的尖刀。 2026年7月，首个口服PROTAC药物GLR2038片获NMPA临床试验批准，针对晚期乳腺癌。另一款AR PROTAC GLR2037也已进入临床阶段，针对前列腺癌等实体瘤。 PROTAC通过三元复合物诱导靶蛋白泛素化降解，与传统抑制型小分子相比具备催化循环、靶向非酶活位点等优势。甘李在此布局，显示它已从代谢专精跨入前沿化学药创新行列。 3.抗体技术平台上，度普利尤单抗生物类似药已获批临床，切入特应性皮炎等自身免疫适应症，同时为未来开发双抗、ADC预留了接口。 4.细胞治疗平台目前尚处早期，作为面向未来的战略性储备，探索肿瘤及代谢病方向。 5.小核酸技术平台同样低调，2025至2026年间开始招聘相关方向人才，着手建立寡核苷酸合成与序列筛选能力，但目前仍属技术储备，尚无公开临床管线。五条线铺得很开，但阶段各不相同。多肽已进入收获期，PROTAC和抗体处于临床验证的深水区，细胞治疗和小核酸还停在纸面。平台多不等于管线强。 PROTAC的临床耐受性是最大的未知数，全球尚无PROTAC药物获批上市，所有在研分子都在回答同一个问题：能否在降解靶蛋白的同时，不引发不可控的脱靶毒性。生物类似药赛道的竞争格局日趋拥挤，度普利尤单抗在特应性皮炎领域的市场空间正在被众多后来者切分。细胞治疗和小核酸离产出还有漫长距离，甘李在这两个领域尚无先发优势。图：甘李药业五大研发平台分层路线图研发投入每年超过6亿元，占营收21%以上，这个强度的投入需要更高效的转化来支撑，否则现金流将持续承压。 04 适应症版图技术平台的铺开，直接推动了适应症疆域的扩张。减重方向以博凡格鲁肽为核心，覆盖单纯超重、肥胖合并糖尿病、肥胖合并睡眠呼吸暂停等多个人群，预计2026年底或2027年初提交上市申请。肿瘤方向依托PROTAC平台布局乳腺癌、前列腺癌等实体瘤。自身免疫方向以度普利尤单抗生物类似药切入特应性皮炎。降血脂方向储备小核酸与口服多肽技术靶向PCSK9等靶点。糖尿病根基则继续迭代，巩固集采后的基本盘。这种跨适应症的扩张并非盲目多元化，而是围绕“内分泌—代谢—免疫—肿瘤”之间的病理交集做同心圆拓展。甘李已有覆盖全国超过四万家医疗机构的渠道网，2025年新斩获海外15个注册批件，产品已拓展至全球21个国家。但渠道优势可以复用，不等于适应症可以顺利铺开。减重市场的商业化节奏是最大的变量，GLP-1类药物在国内减重适应症上的医保准入路径尚不明朗，如果只能走自费渠道，放量速度将大打折扣。肿瘤管线尚处早期临床，乳腺癌和前列腺癌领域已有大量成熟疗法，一款PROTAC分子要从I期走到上市，平均需要8到10年，成功率不到10%。自身免疫领域，度普利尤单抗生物类似药在国内面临至少5家以上的竞争对手，价格战几乎是不可避免的终局。也即是说，每一条新线，都是对管理带宽和现金储备的持续消耗。 05 全球化：远航甘李的国际化布局在产品端和地缘端同步推进。胰岛素制剂已获欧盟EMA GMP认证，门冬胰岛素在2026年5月获欧盟委员会批准上市。巴西十年期技术转移与供应协议，不低于30亿元订单，验证了“政府主导加企业赋能”的出海模式。博凡格鲁肽和GZR4均同步开展海外试验，试图在欧美市场与诺和诺德、礼来正面交锋。但正面交锋的难度不容低估。欧美胰岛素市场由诺和诺德、礼来、赛诺菲三家牢牢把控，医生处方习惯和患者品牌认知是数十年沉淀的结果，不是靠价格优势就能迅速撬动的。巴西的政府间合作模式依赖于当地公共采购体系和政策稳定性，这种模式在短期内很难复制到其他监管环境和市场结构不同的地区。海外临床试验本身也充满变数。GLP-1和胰岛素周制剂在欧美人群中的疗效和安全性数据，需要与国内数据分别验证，任何一组数据不达预期，都可能导致海外注册延期甚至搁浅。 05 结语二十八年，甘李从攻克重组胰岛素类似物产业化的最难路径起步，走到了今天多点开花的版图。锚还扎在胰岛素上，帆已经升向了更远的海面。但船越大，吃水越深。管线越多，兑现的周期越长。在代谢、肿瘤、自免这几条赛道上，甘李面对的都是全球最强劲的竞争对手，而自身的研发转化率和商业化执行力还没有经过多线作战的充分检验。从中国胰岛素龙头到全球综合型生物科技巨头，中间隔着的仍将是一段需要反复穿越的漫长航程。帆已经升起来了，风向也正好。剩下的，是时间和耐心。信息来源：医曜往期推荐 ! 免责声明 “汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。喜欢的点个“看一看”和"喜欢"吧不然微信推送规则改变，有可能每天都会错过我们哦~

2026-07-28

·BioSpace

Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687

The Phase 2a study will evaluate AT7687 as a differentiated combination treatment approach for people living with obesity and type 2 diabetes A 13-week study of 150 randomized participants receiving either once-weekly subcutaneous AT7687 or placebo, each in combination with semaglutide dose escalation. Topline results expected in H1 2027 Copenhagen, Denmark, 28 July 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the dosing of the first patient in its Phase 2a trial evaluating AT7687, the Company’s first-in-class Glucose Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist, in combination with semaglutide for the treatment of people with obesity and type 2 diabetes. As the first clinical-stage peptide-based GIPR antagonist, AT7687 is specifically designed to target and deactivate the GIP receptor, a genetically-validated drug target contributing negatively to adiposity, insulin resistance, and cardiometabolic dysfunction. GIP receptor antagonism is a differentiated therapeutic approach designed to complement existing incretin therapies and providing opportunities for more personalized treatment of clinical obesity. By targeting a distinct biological pathway, Antag aims to deliver sustained metabolic health benefits, while maintaining a favorable tolerability profile. The Phase 2a study ( NCT07724340 ) is a multi-center, randomized, double-blinded 13-week trial evaluating the safety and efficacy of AT7687 in combination with semaglutide for people living with overweight or obesity and type 2 diabetes who are not currently receiving anti-obesity medications. 150 participants will be randomized to receive either once-weekly subcutaneous injection of AT7687 weekly with semaglutide dose escalation, or placebo with semaglutide dose escalation, over a 13-week treatment period, followed by one-month safety follow-up. The primary endpoint of the study is change in body weight from randomization, with change in HbA1c as the key secondary endpoint. Additional secondary and exploratory endpoints will assess treatment effects across a range of clinical measures and biomarkers associated with chronic inflammation, metabolic health and long-term cardiovascular outcomes. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); The study will be conducted in multiple sites in the United States, with topline results expected in H1 2027. Philip Just Larsen, Chief Executive Officer of Antag Therapeutics, said: “The initiation of our Phase 2a trial marks an important milestone for Antag as we continue to advance our vision of expanding the treatment options available to people living with clinical obesity. We believe GIP receptor antagonism represents a fundamentally different approach with the potential to complement today's therapies without adding to the therapeutic burden and give patients greater optionality and we look forward to the data readout next year.” Richard Nkulikiyinka, Chief Medical Officer of Antag, said: “We believe the future of obesity care will increasingly involve combination approaches that balance efficacy, tolerability, and long-term health outcomes. Obesity is a complex, heterogeneous disease that requires more personalized therapeutic strategies rather than a one-size-fits-all therapeutic approach. This Phase 2a trial will provide important insights into the potential of AT7687 as a combination therapy, building on our comprehensive Phase 1 safety and tolerability data, as we aim to deliver clinically meaningful metabolic benefits to people living with obesity.” The Phase 2a trial builds on positive Phase 1 results announced earlier this year, which demonstrated favorable safety and tolerability pro both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. No severe or serious adverse events were observed in the study and importantly, no gastrointestinal tolerability signals were identified. -ENDS- About Antag Therapeutics Antag Therapeutics is a biotechnology company redefining obesity treatment with GIPR antagonism. Antag’s vision is that all people living with clinical obesity, and diabetes, have a personal treatment option, that goes beyond weight loss to deliver long-term sustained health, without having to compromise on tolerability. Based on decades of research by GLP-1 pioneer Professor Jens Juul Holst, Antag’s lead molecule, AT7687, is specifically designed to target and deactivate the GIP receptor, a genetically-validated drug target that contributes to adiposity, insulin resistance, and cardiometabolic dysfunction. In pre-clinical studies, AT7687 exhibits an excellent tolerability profile, with no need for titration, and improvements across a range of biomarkers related to better cardiovascular outcomes, healthier body composition. Moreover, AT7687 is a peptide specifically engineered and selected for its straightforward and versatile formulation properties, uniquely positioning Antag to develop AT7687 as monotherapy or as co-formulation with other obesity therapies. This mechanistically distinct approach suggests a paradigm shift in the treatment of obesity, enabling a new kind of treatment – designed to support more personal, adaptable care – with the aim of delivering healthier, long-term outcomes for all people with clinical obesity. A Phase 2a study evaluating AT7687 is currently underway, with topline results expected in H1 2027. Antag Therapeutics has raised €80 million in a Series A financing led by Versant Ventures with participation from Novo Holdings, SR One, Dawn Biopharma, Pictet, Longview Ventures, and the Export and Investment Fund of Denmark (EIFO). Learn more at . Contacts Antag Therapeutics Philip Just Larsen Chief Executive Officer, Antag Therapeutics antag@antagtx.com Antag Therapeutics Media Contacts ICR Healthcare Amber Fennell, Angela Gray, Evi Useh Email: antagtx@icrhealthcare.com

临床2期临床1期

100 项与司美格鲁肽 (诺和诺德) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10025	司美格鲁肽 (诺和诺德)	A10BJ06	DB13928

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心脏病	英国	Novo Nordisk A/S	2026-04-01
肝纤维化	美国	Novo Nordisk, Inc.	2025-12-22
肺纤维化	加拿大	Novo Nordisk Canada, Inc.	2025-12-21
代谢功能障碍相关脂肪性肝炎	美国	Novo Nordisk, Inc.	2025-08-15
代谢功能障碍相关脂肪性肝炎	美国	Novo Nordisk A/S	2025-08-15
慢性肾病	美国	Novo Nordisk A/S	2025-01-28
慢性肾病	美国	Novo Nordisk, Inc.	2025-01-28
脑卒中	澳大利亚	Novo Nordisk Pharmaceuticals Pty Ltd.	2024-12-16
心肌梗塞	加拿大	Novo Nordisk Canada, Inc.	2024-11-27
心血管疾病	美国	Novo Nordisk, Inc.	2024-03-08
肥胖	美国	Novo Nordisk, Inc.	2021-06-04
超重	美国	Novo Nordisk, Inc.	2021-06-04
2型糖尿病	美国	Novo Nordisk, Inc.	2017-12-05

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
白蛋白尿	临床3期	加拿大	Novo Nordisk A/S	2022-03-14
白蛋白尿	临床3期	德国	Novo Nordisk A/S	2022-03-14
白蛋白尿	临床3期	荷兰	Novo Nordisk A/S	2022-03-14
白蛋白尿	临床3期	西班牙	Novo Nordisk A/S	2022-03-14
膝关节炎	临床3期	美国	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	加拿大	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	哥伦比亚	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	丹麦	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	法国	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	挪威	Novo Nordisk A/S	2021-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ADA2026	N/A	2型糖尿病	104	Semaglutide 0.5-1.0 mg weekly (Type 2 Diabetes)	願構窪繭鏇淵衊顧顧觸(膚簾製夢鬱艱鏇鹽範餘) = 願齋鬱醖鹽網糧觸製範獵齋觸築築觸構憲餘襯 (鹹壓獵鹹窪醖壓願淵網 ) 更多	积极	2026-06-20
ADA2026	N/A	2型糖尿病 \| 外周动脉疾病	24,374	Tirzepatide	艱齋蓋築製廠膚壓製餘(餘壓鏇鏇獵願鏇顧鬱廠): RR = 0.65 (95.0% CI, 0.45 ~ 0.92), P-Value = 0.015	积极	2026-06-20
				Injectable Semaglutide
ADA2026	N/A	2型糖尿病	12,500	Tirzepatide	網簾壓網醖襯網鏇遞獵(憲窪顧餘醖鬱築鑰窪憲): RR = 1.08 (95.0% CI, 0.97 ~ 1.2)	积极	2026-06-20
				Semaglutide
NCT05537233 (ADJUST-T1D, ADA2026)	临床3期	1型糖尿病	72	Semaglutide	範鏇廠觸願遞憲獵網鏇(壓範選壓鑰醖廠遞簾願) = 齋構衊顧願遞觸獵製遞艱蓋鬱齋範築蓋製蓋網 (繭築襯鹽夢獵製鏇襯廠 )	积极	2026-06-20
				Placebo	範鏇廠觸願遞憲獵網鏇(壓範選壓鑰醖廠遞簾願) = 築獵廠願衊廠餘積鑰築艱蓋鬱齋範築蓋製蓋網 (繭築襯鹽夢獵製鏇襯廠 )
NCT04707469 (PIONEER PLUS, ADA2026)	临床3期	2型糖尿病	262	Oral Semaglutide 14 mg	積簾窪鑰鹹選齋鹹憲鹹(網願遞夢鹹鬱選遞鹹醖) = 齋廠蓋遞鏇蓋築衊築遞糧鹹膚壓糧遞廠鏇衊憲 (淵網艱衊鹹願選鹽廠齋 ) 更多	积极	2026-06-20
				Oral Semaglutide 25 mg	積簾窪鑰鹹選齋鹹憲鹹(網願遞夢鹹鬱選遞鹹醖) = 構網糧顧艱築獵構醖繭糧鹹膚壓糧遞廠鏇衊憲 (淵網艱衊鹹願選鹽廠齋 )
ADA2026	N/A	2型糖尿病	45	Semaglutide (Kidney Transplant Recipients + Type 2 Diabetes)	網襯齋積選鏇艱選鬱夢(鏇網憲壓衊築夢繭積醖) = 鹹鹽蓋鹽構繭鬱願齋艱繭齋網齋選願願範鏇衊 (範壓簾鹹齋淵壓簾壓餘 )	积极	2026-06-20
SELECT (ADA2026)	临床3期	哮喘 blood high-sensitivity C-reactive protein [hsCRP]	1,190	Semaglutide 2.4 mg	繭鏇齋窪夢觸醖鬱鬱願(憲範窪廠齋鬱願廠積鬱) = 築憲製鑰繭築蓋鏇艱顧醖願夢鏇齋壓築鬱夢網 (廠蓋壓醖窪構鏇襯簾鑰 ) 更多	积极	2026-06-20
				Placebo	繭鏇齋窪夢觸醖鬱鬱願(憲範窪廠齋鬱願廠積鬱) = 遞簾膚窪觸糧製膚醖鏇醖願夢鏇齋壓築鬱夢網 (廠蓋壓醖窪構鏇襯簾鑰 ) 更多
SELECT (ADA2026)	N/A	心血管疾病 \| 肥胖	17,017	Semaglutide 2.4mg (Asian)	衊鹹遞鏇齋蓋願獵艱齋(獵鹹網簾簾淵範範鬱壓) = 襯獵顧廠範窪繭獵遞廠願壓構壓範鏇壓鹹簾範 (遞鹹餘艱範構積觸鏇製 )	积极	2026-06-20
				Semaglutide 2.4mg (Hispanic)	衊鹹遞鏇齋蓋願獵艱齋(獵鹹網簾簾淵範範鬱壓) = 襯範網選鬱淵顧醖獵獵願壓構壓範鏇壓鹹簾範 (遞鹹餘艱範構積觸鏇製 )
ADA2026	N/A	肥胖	177	Oral Semaglutide (Rybelsus) (Diabetes)	鬱憲衊鏇積壓壓鏇構蓋(艱壓廠衊夢憲積選襯簾) = 簾壓夢遞繭餘淵簾範築觸鬱蓋醖顧繭鹽顧衊網 (糧蓋蓋夢艱積鑰遞壓醖 ) 更多	积极	2026-06-20
ADA2026	N/A	2型糖尿病	66	Insulin Icodec + Semaglutide (Uncontrolled Type 2 Diabetes)	壓憲鹽選艱獵簾鏇壓鬱(窪艱鑰淵願襯艱鏇範鑰) = improved significantly from 54.8±23.3% at baseline to 78.1±18.9% (95% CI 9.5-25.5, P<0.001) 醖築積窪艱顧夢壓製膚 (鬱範簾齋淵製壓夢窪觸 ) 更多	积极	2026-06-20